Corvus Pharmaceuticals, Inc. Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals
Corvus Pharmaceuticals, Inc. (CRVS) had Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals of $124.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals
us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals · last filed 2023-03-28
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $124.00K.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $137.00K.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $207.00K.
- 2019-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $152.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals |
|---|---|
| 2022-12-31 | $124.00K 10-K · filed 2023-03-28 |
| 2021-12-31 | $137.00K 10-K · filed 2023-03-28 |
| 2020-12-31 | $207.00K 10-K · filed 2023-03-28 |
| 2019-12-31 | $152.00K 10-K · filed 2022-03-10 |
| 2018-12-31 | $188.00K 10-K · filed 2021-03-25 |
| 2017-12-31 | $183.00K 10-K · filed 2020-03-09 |
| 2016-12-31 | $230.00K 10-K · filed 2019-03-07 |
| 2015-12-31 | $108.00K 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |